Drug intelligence / Profile preview

PRX-034

Development stage: Unknown
Lead developer: Primmune Therapeutics
Modality: Small Molecules
Administration: Intravenous

Overview

**PRX-034** is a small-molecule **TLR7 agonist** developed by Primmune Therapeutics for oncology and infectious diseases. It preferentially activates plasmacytoid dendritic cells (pDCs) to induce a robust interferon (IFN) response, including IFNα, with minimal proinflammatory cytokines like TNFα and IL-6, enabling systemic immune activation suitable for combination with immune checkpoint inhibitors (ICPIs). PRX-034 binds the guanosine site of TLR7, shows higher potency in human PBMCs (EC50 15 µM for pDC activation) than monkey cells, and is delivered systemically via oral prodrug PRTX007 after hepatic conversion.[1][3][9][11][14]

Other names: PRX034PRX-034PRX 034polvitolimodcompound 27compound27compound-27

Targets

TLR7 (Toll-like receptor 7)

Beyond the preview

Go deeper on PRX-034.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRX-034.

Explore the full profile